Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Efficacy of Lamazym in Alpha-Mannosidosis
NCT02478840Phase 3Completed
- Sponsor
- Zymenex
- Start
- Feb 2015
- Primary completion
- Jun 2015
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of velmanase alfa in alpha-mannosidosis, sponsored by Zymenex. Primary endpoints: Change from baseline in reduction of oligosaccharides in serum at 4 years and Change from baseline in 3 Minutes Stair Climb Test at 4 years. Started Feb 2015; status: completed.
02
Drugs
velmanase alfa
03
Conditions
alpha-mannosidosis
Beyond the preview
Go deeper on NCT02478840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02478840.